（1）国家自然科学基金面上项目, 2026-01-01 至 2029-12-31，50万元，在研，主持
（2）江苏省自然科学基金面上项目，2025-09-01 至 2028-12-31，15万元，在研，主持
（3）国家自然科学基金青年基金项目，82103978，2022-01-01 至 2024-12-31，30万元，已结题，主持
（4）江苏省自然科学基金青年基金项目，BK20210423，2021-07 至 2024-06，20万元，已结题，主持
（5）中国博士后基金面上项目，2019M662007，2019-11至2022-06，8万元，已结题，主持
（6）2020年度江苏省博士后日常资助，2020-09至2022-07，16万元，已结题，主持

1.Yao, J.Y.1; Wang, J.B. 1; Xu, Y.; Guo, Q.L.*; Sun, Y.N.; Liu, J.; Li, S.C.; Guo, Y.J.; Wei, L.B.* CDK9 inhibition blocks the initiation of PINK1 PRKN mediated mitophagy by regulating the SIRT1 FOXO3 BNIP3 axis and enhances the therapeutic effects. Autophagy. 2021;10.1080/15548627.2021.2007027. (IF:16.016)
2.Xu, X. 1; Wang, J.B. 1; Wang, M.; Yuan, X.Y.; Li, L.; Zhang, C.; Huang, H.D.*; Jing, T.; Wang, C.C.; Tong, C.; Zhou,L.W.; Meng, Y.; Xu, P.F.; Kou, J.P.; Qiu, Z.X.; Li, Z.Y.*; Bian, J.L.* Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site. Journal of Medicinal Chemistry. 2021;64:4588-4611. (IF:7.446)
3.Qin, Z.; Dong, B.; Wang, R.B,; Huang, D.C.; Wang, J.B.*; Feng, X.; Bian, J.L.*; Li, Z.Y.* Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation via machine learning. Acta Pharmaceutica Sinica B. 2021;11:3678-3682. (IF:11.413)
4.Qiu, X.Q.; Li, Y.Q.; Yu, B.; Ren, J.; Huang, H.D.; Wang, M.; Ding, H.; Li, Z.Y.*; Wang, J.B.*; Bian, J.L.* Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion. European Journal of Medicinal Chemistry. 2021;211:113091. (IF:6.514)
5.Hu, P. 1; Wang, J.B. 1; Qing, Y.J.; Sun, W.Z.; Yu, X.X.; Hui, H.; Guo, Q.L.*; Xu, J.Y.* FV-429 induces autophagy blockage and lysosome-dependent cell death of T-cell malignancies via lysosomal dysregulation. Cell Death & Disease. 2021;12:80. (IF:8.469)
6.Wu, H.X.; Ren, J.; Zhao, L.L.; Li, Z.Y.*; Ye, W.L.; Yang, Y.; Wang, J.B.*; Bian, J.L.* Identification of novel androgen receptor degrading agents to treat advanced prostate cancer. European Journal of Medicinal Chemistry. 2021;217:113376. (IF:6.514)
7.Xu, P.F.; Shen, P.; Wang, H.; Qin, L.; Ren, J.; Sun, Q.S.; Ge, R.L.; Bian, J.L.; Zhong, Y.; Li, Z.Y.*; Wang, J.B.*; Qiu, Z.X.* Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2. European Journal of Medicinal Chemistry. 2021;218:113394. (IF:5.572)
8.Tian, Y.C. 1; Wang, J.B. 1; Cheng, X.Y.; Liu, K.; Wu, T.Z.; Qiu, X.Q.; Kuang, Z.J.; Li, Z.Y.*; Bian, J.L.* Microwave-assisted unprotected Sonogashira reaction in water for the synthesis of polysubstituted aromatic acetylene compounds. Green Chemistry. 2020;22:1338-1344. (IF:9.48)
9.Xu, P.F.; Shen, P.; Yu, B.; Xu, X.; Ge, R.L.; Cheng, X.Y.; Chen, Q.Y.; Bian, J.L.; Li, Z.Y.*; Wang, J.B.* Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. European Journal of Medicinal Chemistry. 2020;192:112155. (IF:5.572)
10.Xu, X.; Du, Q.M.; Meng, Y.; Li, Z.Y.*; Wu, H.X.; Li, Y.; Zhao, Z.L.; Ge, R.L.; Lu, X.Y.; Xue, S.Q.; Chen, X.J.; Yang, H.; Wang, J.B.*; Bian, J.L.* Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists. European Journal of Medicinal Chemistry. 2020;192:112196. (IF:5.572)